KÃ¥re Schultz appointed new president and CEO of Lundbeck


KÃ¥re Schultz will take up his new position on May 20, 2015.


Valby, Denmark, 6 May 2015 - H. Lundbeck A/S (Lundbeck) today announced that the Board of Directors of the company has appointed Kåre Schultz as new president and CEO of Lundbeck. Kåre Schultz will take up his new position on 20 May 2015.

"It is a great pleasure to announce that Kåre Schultz will join Lundbeck as president and CEO. With his unique experience from an impressive career in the pharmaceutical industry, Kåre Schultz has all the qualifications to handle the challenges Lundbeck faces," says Håkan Björklund, Chairman of Lundbeck's Board of Directors.

Lundbeck's future president and CEO has been the president and COO of Novo Nordisk A/S since January 2014. He joined Novo Nordisk in 1989.

Kåre Schultz is chairman of the board of Royal Unibrew A/S and a member of the board of LEGO A/S, both in Denmark. He has an MSc in Economics from the University of Copenhagen, Denmark, from 1987. Kåre Schultz is a Danish national, born May 1961.

"Lundbeck stands out in the industry as a company focused on brain diseases. I'm motivated and inspired by Lundbeck's vision and excited to bring my business background to lead Lundbeck to the next phase of its development", says Kåre Schultz and continues "Lundbeck is going through challenging times and I look forward to working with everyone at Lundbeck to build a strong future for our patients, shareholders and employees."

Related Videos
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
Medical team -- Image credit: Flamingo Images | stock.adobe.com
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.